BioNexus Gene Lab (BGLC) Revenue (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Revenue data on file, last reported at $22842.0 in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 98.93% year-over-year to $22842.0; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 42.69% YoY), and the FY2025 full-year result was $7.4 million, down 21.93% from the prior year.
• Revenue slipped to $22842.0 in Q1 2026, from $483760.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $3.0 million in Q1 2022 to a low of $22842.0 in Q1 2026.
• A 5-year average of $2.2 million and a median of $2.5 million in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue jumped 611.35% in 2022 and tumbled 98.93% in 2026, its largest moves.
• Tracing BGLC's Revenue over 5 years: stood at $2.8 million in 2022, then slipped by 19.95% to $2.3 million in 2023, then increased by 11.03% to $2.5 million in 2024, then tumbled by 80.83% to $483760.0 in 2025, then tumbled by 95.28% to $22842.0 in 2026.
• Business Quant data shows BGLC's Revenue at $22842.0 in Q1 2026, $483760.0 in Q4 2025, and $2.5 million in Q3 2025.